Earnings Call Summary | 2seventy Bio(TSVT.US) Q2 2024 Earnings Conference
Earnings Call Summary | 2seventy Bio(TSVT.US) Q2 2024 Earnings Conference
The following is a summary of the 2seventy Bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript:
以下是2seventy Bio, Inc. (TSVT) 2024年第二季度業績會議電話交流摘要：
Financial Performance:
金融業績：
ABECMA US revenues reported by Bristol-Myers Squibb were $54 million, consistent with expectations.
Q2 brought $43 million from sales of oncology R&D to Regeneron and hemophilia A program to Novo Nordisk.
Achieved $24.9 million in GAAP net income for the quarter from strategic sales and efficiency gains.
施貴寶ABECMA在美國的營業收入爲5400萬美元，與預期一致。
第二季度銷售癌症R＆D和血友病A項目分別向Regeneron和Novo Nordisk帶來了4300萬美元的收入。
本季度通過戰略銷售和效率提高實現了2490萬美元的總會計淨收入。
Business Progress:
業務進展：
Focused exclusively on ABECMA post-strategic sales including oncology R&D and hemophilia A program.
Commenced third-line launch of ABECMA, showing double-digit growth in apheresis as a precursor to revenue growth.
Streamlined operations resulted in significant decrease in operating expenses, anticipating continuous decline into 2025.
專注於ABECMA發帖後的戰略銷售，包括腫瘤R＆D和血友病A項目。
啓動ABECMA的第三線推出，顯示出血漿分離的二位數增長作爲營收增長的先兆。
精簡運營導致營業費用顯著下降，預計持續下降到2025年。
Opportunities:
機會：
Anticipate ABECMA's return to growth in upcoming months bolstered by broad data and expanded FDA approval.
Following strategic divestitures, positioned to prioritize efficiency and drive towards cash flow breakeven and profitability in 2025.
預計ABECMA將在未來幾個月內恢復增長，獲得廣泛數據和擴大的FDA批准的支持。
在戰略剝離之後，定位於提高效率和推動現金流平衡和盈利能力。
Risks:
風險：
ABECMA faces gradual growth challenges in scaling, depending on the uptake and continued competitive efficacy in its new broader usage realms.
ABECMA在規模擴大方面面臨逐漸增長的挑戰，具體取決於新的更廣泛使用領域的吸收和持續的競爭效力。
More details: 2seventy bio IR
更多詳情：2seventy bio IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。